65,437 trials
Cocaine Dependence
Primary: Brain Glutamate Concentration in the Anterior Cingulate Cortex (ACC) in Subjects With Cocaine Use Disorder (CUD) Treated With Escalating Doses of Clavulanate (CLAV)…
Dry Eye Disease
Primary: Number of Subjects With Adverse Events — 13; 15; 10 Participants
Acute Myocardial Infarction
Primary: Number of Participants With First CEC (Clinical Endpoint Committee) Confirmed Primary Composite Endpoint — 338; 373; 168; 191 Count of Participants — p=0.1659
Visual Acuity
Primary: End of Day Comfort — 76; 46; 52; 58 Number of responses
Anaplastic Large Cell Lymphoma · Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma · Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Primary: Number of Patients With Grade 3 or Above Toxicities — 9 Participants
Diabetes Mellitus, Type 2
Primary: Hemoglobin A1C — -0.20; -0.13 percent of hemoglobin A1c
Chronic Kidney Disease · Hypertension
Primary: Change in Urinary Albumin Excretion From Baseline to 4 Months — -28.6; -5.6 mg/g — p=0.17
Normal Physiology
Primary: Number of Participants Sampled for RNA-seq Differential Expression Analysis (Biological Replicates) — 5; 20 Participants
College Student Drinking
Primary: Alcohol Consumption at 3 Months Post-intervention — 4.08; 4.15; 4.89 drinks per week
Hereditary Angioedema · HAE · Prophylaxis
Primary: Safety & Tolerability — 94; 240; 58; 119 Participants
Androgenic Alopecia
Primary: Total Area Hair Count — 126.8 hairs per cm^2
Cytomegalovirus Positive · Glioblastoma · Gliosarcoma
Primary: Maximum Tolerated Dose (MTD) (Recurrent Glioblastoma Participant Cohort)- Phase I — 3; 3; 3; 7 participants
Lateral Canthal Lines
Primary: Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Lateral Canthal Line Investigator and Subject Assessments at Maximum Smile at One Month. — 106…
Parkinson Disease
Primary: Gait Velocity — 1.25; 1.25 Meters per second
HIV/AIDS
Primary: Sexual Risk Behavior — 1; 2 Participants